Deprescripción: 11 medicamentos para reconsiderar

Una revisión de las evidencias que respaldan la suspensión de once clases de fármacos en al menos algunas de las situaciones en que se utilizan.

Medscape, 5 de septiembre de 2017

La polifarmacia se describe como tomar 5 o más medicamentos en forma diaria, y es especialmente frecuente en los ancianos. Habitualmente es posible reducir el número de medicamentos indicados, con el potencial de disminuir efectos adversos, interacciones medicamentosas y costos.

Este artículo revisa once situaciones en las que medicamentos de diferentes clases farmacológicas podrían no tener un balance favorable de eficacia y riesgos, por lo menos para muchos de los pacientes que los reciben.

Para ver los detalles, siga el enlace correspondiente:

1) Docusato como laxante (referencias 2-3 )

2) Profilaxis antibiótica previa a procedimientos odontológicos (referencias4-8)

3) Inhibidores de la bomba de protones (referencias 9-10)

4) Estatinas en prevención primaria (referencias 11-13)

5) Benzodiacepinas y “fármacos Z” (referencias 14-16)

6) Beta bloqueadores (referencias 17-21)

7) Fármacos para Asma / EPOC (referencias 22-24)

8) Antimuscarínicos para incontinencia urinaria (referencias 25-16)

9) Inhibidores de anticolinesterasa para la demencia (referencias 27-29)

10) Relajantes musculares para el dolor lumbar (referencia 30)

11) Suplementos de vitaminas y minerales (referencias 31-32)

Referencias

1. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989-995.
2. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337-344.
3. McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998;12:491-917.
4. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. Clin Infect Dis. 1997;25:1448-1458.
5. Berbari EF, Osmon DR, Carr A, et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis. 2010;50:8-16.
6. Hamedani S. A clinical practice update on the latest AAOS/ADA guideline (December 2012) on prevention of orthopaedic implant infection in dental patients. J Dentistry. 2013;14:49-52.
7. Kao FC, Hsu YC, Chen WH, Lin JN, Lo YY, Tu YK. Prosthetic joint infection following invasive dental procedures and antibiotic prophylaxis in patients with hip or knee arthroplasty. Infect Control Hosp Epidemiol. 2017;38:154-161.
8. National Institute of Dental and Craniofacial Research. Dental Management of the Organ or Stem Cell Transplant Patient. https://www.nidcr.nih.gov/OralHealth/Topics/OrganTransplantationOralHealth/OrganTransplantProf.htm Accessed August 23, 2017.
9. Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7:e015735.
10. Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3:CD011969.
11. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934.
12. Han BH, Sutin D, Williamson JD, et al; ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults: the ALLHAT-LLT randomized clinical trial. JAMA Intern Med. 2017;177:955-965.
13. Ridker PM, Lonn E, Paynter NP, Glynn R, Yusuf S. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary JUPITER and HOPE-3 randomized trials. Circulation. 2017;135:1979-1981.
14. Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: A systematic review. Maturitas. 2017;101:17-22.
15. Yu NW, Chen PJ, Tsai HJ, et al. Association of benzodiazepine and Z-drug use with the risk of hospitalisation for fall-related injuries among older people: a nationwide nested case-control study in Taiwan. BMC Geriatr. 2017;17:140.
16. Park H, Satoh H, Miki A, Urushihara H, Sawada Y. Medications associated with falls in older people: systematic review of publications from a recent 5-year period. Eur J Clin Pharmacol. 2015;71:1429-1440.
17. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432-2446.
18. Dondo TB, Hall M, West RM, et al. Beta-blockers and mortality after acute myocardial infarction in patients without heart failure or ventricular dysfunction. J Am Coll Cardiol. 2017;69:2710-2720.
19. Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014;127:939-853.
20. Testa G, Cacciatore F, Della-Morte D, et al. Atenolol use is associated with long-term mortality in community-dwelling older adults with hypertension. Geriatr Gerontol Int. 2014;14:153-158.
21. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684-1689.
22. Aaron SD, Vandemheen KL, FitzGerald JM, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA. 2017;317:269-279.
23. Heffler E, Pizzimenti S, Guida G, Bucca C, Rolla G. Prevalence of over-/misdiagnosis of asthma in patients referred to an allergy clinic. J Asthma. 2015;52:931-934.
24. Jain VV, Allison DR, Andrews S, Mejia J, Mills PK, Peterson MW. Misdiagnosis among frequent exacerbators of clinically diagnosed asthma and COPD in absence of confirmation of airflow obstruction. Lung. 2015;193:505-512.
25. Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012;156:861.
26. Agency for Healthcare Research and Quality. Nonsurgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness. Comparative Effectiveness Review No. 36. April, 2012. http://www.pcori.org/sites/default/files/PCORI-Executive-Summary-NonSurgical-Treatment-of-Urinary-Incontinence-120716.pdf Accessed August 14, 2017.
27. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ. 2005;331:321-327.
28. Sheffrin M, Miao Y, Boscardin WJ, Steinman MA. Weight loss associated with cholinesterase inhibitors in individuals with dementia in a national healthcare system. J Am Geriatr Soc. 2015;63:1512-1518.
29. Starr JM. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's'disease. J Am Geriatr Soc. 2007;55:800-801.
30. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM, Cochrane Back Review Group. Muscle relaxants for nonspecific low back pain: a systematic review within the framework of the Cochrane collaboration. Spine (Phila Pa 1976). 2003;28:1978-1992.
31. Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159:824-834.
32. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-683.

El artículo original:

Paauw DS. 11 drugs you should seriously consider deprescribing. Medscape Internal Medicine [Internet] September 5, 2017. http://www.medscape.com/slideshow/deprescribing-6009041?src=WNL_infoc_17...

Disponible en: http://wb.md/2j323WQ